Our focus
Major Depression affects at least one in ten people worldwide, inflicting not only devastating individual suffering but also standing as the leading cause of suicides. Depression causes extensive economic damage stemming from treatment costs, work disability, and early retirement.
These facts have prompted INNOVADE Therapeutics to address this challenge by developing groundbreaking solutions for the innovation crisis in the treatment of depression.
From neuroscience research...
Backed by a robust and successful academic background and many collaborations worldwide, our team of scientists and researchers has identified novel classes of antidepressants through fundamental neuroscience research.
These medications work by enhancing plasticity and restructuring synapses and networks within the human brain.
Our primary small molecule candidate targets a subunit of specific receptors on inhibitory nerve cells in the brain, resulting in a rapidly effective antidepressant with fewer side effects.
... to Drug Development
Our development endeavors encompass a comprehensive platform approach
Demonstrates efficacy and the mechanism of action in animal models
Ensures compound safety through comprehensive toxicology and pharmacological studies
Develops optimal drug delivery systems and establishes manufacturing processes
Advances therapeutic candidates through clinical trials to validate safety and efficacy in humans
At INNOVADE Therapeutics, we play a pivotal role in advancing highly innovative, fast-acting, and low-side-effect antidepressant therapy options. Our commitment extends beyond enhancing the quality of life for those affected; we are also dedicated to identifying avenues for exploitation and achieving success in the market. Together, we take a significant step forward to effectively combat the widespread challenge of depression.
Upcoming
9–11
Nov 2026
Cologne, Germany
Our team will be in Cologne from the 9th to the 11th of November for this year's event.
Want to connect or schedule a meeting with us during the congress?
10–11
Dec 2026
Marseille, France
Our team will be in Marseille from the 10th to the 11th of December for this year's event.
Want to connect or schedule a meeting with us during the congress?
Featured publication · Nature Communications 2025
A significant part of the scientific foundation behind our approach has been published in Nature Communications, providing peer-reviewed support for GluN2D-containing NMDA receptors as a promising target for rapid antidepressant action.
Vestring S. et al. The NMDA receptor subunit GluN2D is a potential target for rapid antidepressant action. Nat. Commun. 16, 10613 (2025). doi:10.1038/s41467-025-66774-w
Read the publication (PDF)Interested in the science behind our programs or in exploring potential collaborations?
Contact us
